High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.

Boeree, MJ; Heinrich, N; Aarnoutse, R; Diacon, AH; Dawson, R; Rehal, S; Kibiki, GS; Churchyard, G; Sanne, I; Ntinginya, NE; +20 more... Minja, LT; Hunt, RD; Charalambous, S; Hanekom, M; Semvua, HH; Mpagama, SG; Manyama, C; Mtafya, B; Reither, K; Wallis, RS; Venter, A; Narunsky, K; Mekota, A; Henne, S; Colbers, A; van Balen, GP; Gillespie, SH; Phillips, PP; Hoelscher, M; PanACEA consortium; (2016) High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet infectious diseases, 17 (1). pp. 39-49. ISSN 1473-3099 DOI: https://doi.org/10.1016/S1473-3099(16)30274-2

Permanent Identifier

Use this Digital Object Identifier when citing or linking to this resource.

https://doi.org/10.1016/S1473-3099(16)30274-2

Abstract

Share

Download

Filename: High-dose rifampicin, moxifloxacin, and SQ109.pdf

Licence: Creative Commons: Attribution 3.0

Download
[img]

Downloads

View details

Metrics & Citations


Google Scholar